High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Protein & Cell
; (12): 877-888, 2021.
Article
en En
| WPRIM
| ID: wpr-922482
Biblioteca responsable:
WPRO
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Antivirales
/
Inhibidores de Proteasas
/
Sitios de Unión
/
Proteínas Recombinantes
/
Mutagénesis Sitio-Dirigida
/
Naftoquinonas
/
Estructura Terciaria de Proteína
/
Cristalografía por Rayos X
/
Concentración 50 Inhibidora
/
Evaluación Preclínica de Medicamentos
Tipo de estudio:
Diagnostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Protein & Cell
Año:
2021
Tipo del documento:
Article
